PCM
NTLA icon

Princeton Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Princeton Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,000
Closed -$55K – 281
2018
Q2 		$55K Hold
2,000
– – 0.02% 169
2018
Q1 		$42K Buy
+2,000
New +$49.2K 0.02% 177

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Princeton Capital Management's NTLA Position: Q3 2018 in Review

Princeton Capital Management sold out of Intellia Therapeutics (NTLA) in Q3 2018, closing a stake of 2,000 shares — an estimated $55K sold.

Princeton Capital Management first reported a position in NTLA in Q1 2018 and held it in 2 quarters. The position peaked at $55K in Q2 2018. 157 funds tracked by Wall St. Rank hold NTLA as of Q3 2018.

  • Princeton Capital Management reported no remaining Intellia Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Princeton Capital Management sold 2,000 Intellia Therapeutics shares in Q3 2018, an estimated $55K.
  • Princeton Capital Management first reported a position in Intellia Therapeutics in Q1 2018 and held it in 2 quarters.
  • Princeton Capital Management's Intellia Therapeutics position peaked at $55K in Q2 2018.
  • 157 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2018.

Based on Princeton Capital Management's 13F filing for Q3 2018, filed 7 Nov 2018.